Sökning: onr:"swepub:oai:lup.lub.lu.se:f208bf2b-2108-4200-9cec-b47449aec8ca" > The tale of TILs in...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05026naa a2200901 4500 | |
001 | oai:lup.lub.lu.se:f208bf2b-2108-4200-9cec-b47449aec8ca | |
003 | SwePub | |
008 | 211201s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/f208bf2b-2108-4200-9cec-b47449aec8ca2 URI |
024 | 7 | a https://doi.org/10.1038/s41523-021-00346-12 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a for2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a El Bairi, Khalidu Mohamed Premier University4 aut |
245 | 1 0 | a The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group |
264 | c 2021-12-01 | |
264 | 1 | b Springer Science and Business Media LLC,c 2021 |
520 | a The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Haynes, Harry R.4 aut |
700 | 1 | a Blackley, Elizabeth4 aut |
700 | 1 | a Fineberg, Susan4 aut |
700 | 1 | a Shear, Jeffrey4 aut |
700 | 1 | a Turner, Sophia4 aut |
700 | 1 | a De Freitas, Juliana Ribeiro4 aut |
700 | 1 | a Sur, Daniel4 aut |
700 | 1 | a Amendola, Luis Claudio4 aut |
700 | 1 | a Gharib, Masoumeh4 aut |
700 | 1 | a Kallala, Amine4 aut |
700 | 1 | a Arun, Indu4 aut |
700 | 1 | a Azmoudeh-ardalan, Farid4 aut |
700 | 1 | a Fujimoto, Luciana4 aut |
700 | 1 | a Sua, Luz F.4 aut |
700 | 1 | a Liu, Shi-wei4 aut |
700 | 1 | a Lien, Huang-chun4 aut |
700 | 1 | a Kirtani, Pawan4 aut |
700 | 1 | a Balancin, Marcelo4 aut |
700 | 1 | a El Attar, Hicham4 aut |
700 | 1 | a Guleria, Prerna4 aut |
700 | 1 | a Yang, Wenxian4 aut |
700 | 1 | a Shash, Emad4 aut |
700 | 1 | a Chen, I-chun4 aut |
700 | 1 | a Bautista, Veronica4 aut |
700 | 1 | a Do Prado Moura, Jose Fernando4 aut |
700 | 1 | a Rapoport, Bernardo L.4 aut |
700 | 1 | a Castaneda, Carlos4 aut |
700 | 1 | a Spengler, Eunice4 aut |
700 | 1 | a Acosta-haab, Gabriela4 aut |
700 | 1 | a Frahm, Isabel4 aut |
700 | 1 | a Sanchez, Joselyn4 aut |
700 | 1 | a Castillo, Miluska4 aut |
700 | 1 | a Bouchmaa, Najat4 aut |
700 | 1 | a Md Zin, Reena R.4 aut |
700 | 1 | a Shui, Ruohong4 aut |
700 | 1 | a Onyuma, Timothy4 aut |
700 | 1 | a Yang, Wentao4 aut |
700 | 1 | a Husain, Zaheed4 aut |
700 | 1 | a Willard-gallo, Karen4 aut |
700 | 1 | a Coosemans, An4 aut |
700 | 1 | a Perez, Edith A.4 aut |
700 | 1 | a Provenzano, Elena4 aut |
700 | 1 | a Ericsson, Paula Gonzalez4 aut |
700 | 1 | a Richardet, Eduardo4 aut |
700 | 1 | a Mehrotra, Ravi4 aut |
700 | 1 | a Ehinger, Annau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-amm |
700 | 1 | a Brown, Mark4 aut |
700 | 1 | a Lundin, Johan4 aut |
700 | 1 | a Loi, Shereneu University of Melbourne4 aut |
710 | 2 | a Mohamed Premier Universityb LUCC: Lunds universitets cancercentrum4 org |
710 | 2 | a International Immuno-Oncology Biomarker Working Group |
773 | 0 | t npj Breast Cancerd : Springer Science and Business Media LLCg 7:1q 7:1x 2374-4677 |
856 | 4 | u http://dx.doi.org/10.1038/s41523-021-00346-1x freey FULLTEXT |
856 | 4 | u https://www.nature.com/articles/s41523-021-00346-1.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/f208bf2b-2108-4200-9cec-b47449aec8ca |
856 | 4 8 | u https://doi.org/10.1038/s41523-021-00346-1 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy